Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer.

Autor: Singh P; Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA., Ballas L; Department of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA., Sonpavde GP; Department of Hematology and Oncology, Adventist Health Cancer Institute, Orlando, FL, USA., Chen RC; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA., Bangs R; Bladder Cancer Advocacy Network (BCAN), Bethesda, MD, USA., Bauman BC; Department of Radiation Oncology, Springfield Clinic, Springfield, IL, USA., Nagar H; Department of Radiation Oncology, Weill Cornell Medical Center, New York City, NY, USA., Delacroix SE; Department of Urology, Louisiana State University School of Medicine, Metairie, LA, USA., Lerner SP; Department of Urology, Baylor College of Medicine, Houston, TX, USA., Efstathiou JA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: Bladder cancer (Amsterdam, Netherlands) [Bladder Cancer] 2024 Oct 23; Vol. 10 (3), pp. 199-213. Date of Electronic Publication: 2024 Oct 23 (Print Publication: 2024).